Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:eLife
Glavni autori: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P
Format: Artigo
Jezik:Inglês
Izdano: eLife Sciences Publications, Ltd 2021
Teme:
Epidemiology and Global Health
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064747/
https://ncbi.nlm.nih.gov/pubmed/33830018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.68808
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items